OBIO – orchestra biomed holdings, inc. - ordinary shares (US:NASDAQ)

News

Orchestra BioMed (OBIO) had its "sell (d-)" rating reaffirmed by Weiss Ratings.
Orchestra BioMed (OBIO) was upgraded by Wall Street Zen from "strong
Orchestra BioMed (OBIO) had its "buy" rating reaffirmed by Chardan Capital. They now have a $20.00 price target on the stock.
Orchestra BioMed Reports Full Year 2025 Financial Results and Provides Fourth Quarter Business Update [Yahoo! Finance]
Orchestra BioMed Reports Full Year 2025 Financial Results and Provides Fourth Quarter Business Update
Show more
Live Event: Join our next subscriber-only event: "The Data Driven Investor"
Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com